|
Sarcoma
|
0.200 |
Biomarker
|
group |
BEFREE |
Investigating a chimeric anti-mouse PDGFRα antibody as a radiosensitizer in primary mouse sarcomas.
|
30711517 |
2019 |
|
Sarcoma
|
0.200 |
Biomarker
|
group |
BEFREE |
Olaratumab, the first-in-class anti-PDGFRα monoclonal antibody, has been contingently approved in combination with doxorubicin to treat adult patients with advanced soft tissue sarcoma for improving progression-free and overall survival.
|
30032714 |
2019 |
|
Sarcoma
|
0.200 |
Biomarker
|
group |
BEFREE |
Olaratumab (OLA), a monoclonal antibody against platelet-derived growth factor receptor alpha (PDGFRα), has recently been used against soft-tissue sarcoma (STS) combined with doxorubicin (DOX), with limited efficacy.
|
30867142 |
2019 |
|
Sarcoma
|
0.200 |
Biomarker
|
group |
BEFREE |
Recent randomised phase II trial data have indicated that the addition of olaratumab, a novel monoclonal antibody against platelet-derived growth factor receptor alpha (PDGFRα), to doxorubicin confers an unprecedented improvement in overall survival to patients with anthracycline-naïve advanced soft tissue sarcoma.
|
29413687 |
2018 |
|
Sarcoma
|
0.200 |
Biomarker
|
group |
BEFREE |
Olaratumab, a monoclonal antibody targeting human platelet-derived growth factor receptor α, plus doxorubicin significantly improved overall survival in patients with advanced soft-tissue sarcoma (STS) in a prior phase 1b/2 randomized trial.
|
30353601 |
2018 |
|
Sarcoma
|
0.200 |
AlteredExpression
|
group |
BEFREE |
PDGFR-α/β activity and the effects of PDGFR-α/β inhibition were examined in 3 human sarcoma cell lines using in vitro assays and mouse xenograft models.
|
29915281 |
2018 |
|
Sarcoma
|
0.200 |
Biomarker
|
group |
BEFREE |
PDGFRA Antibody for Soft Tissue Sarcoma.
|
28187274 |
2017 |
|
Sarcoma
|
0.200 |
Biomarker
|
group |
BEFREE |
Here, we reviewed the biology of the PDGF/PDGFR axis, particularly focusing on its role in cancer, and then we discussed on the effects of PDGFR-α inhibition in the therapy of advanced soft tissue sarcomas.
|
28917265 |
2017 |
|
Sarcoma
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Gastrointestinal stromal tumors (GIST) are the most common adult sarcomas and the oncogenic driver is usually a KIT or PDGFRA mutation.
|
25836719 |
2015 |
|
Sarcoma
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Gastrointestinal stromal tumors (GISTs) are the most common soft tissue sarcoma of the gastrointestinal tract, resulting from an activating mutation of stem cell factor receptor (KIT), and an activating mutation of the homologous platelet-derived growth factor receptor alpha (PDGFRA) kinase.Most GISTs (90%-95%) are KIT-positive.
|
23326179 |
2013 |
|
Sarcoma
|
0.200 |
GeneticVariation
|
group |
BEFREE |
KIT and PDGFRA mutations in gastrointestinal stromal tumors) and (ii) sarcomas displaying multiple, complex karyotypic abnormalities with no specific pattern, including leiomyo-sarcoma, and pleomorphic liposarcoma.
|
20490332 |
2010 |
|
Sarcoma
|
0.200 |
Biomarker
|
group |
BEFREE |
We analysed eight advanced high-grade sarcomas originating from major vessels (seven intimal and one mural sarcoma) by means of immunohistochemistry and FISH analysis for PDGFRA, PDGFRB, EGFR and KIT receptor tyrosine kinases (RTKs), together with immunoprecipitation/western blotting, sequencing of the corresponding genes, and the search for cognate ligands.
|
17471466 |
2007 |
|
Sarcoma
|
0.200 |
Biomarker
|
group |
BEFREE |
The c-KIT and the platelet-derived growth factor receptor alpha (PDGFRalpha) have been shown to be important for tumor growth and progression in several soft-tissue sarcomas, including synovial sarcomas (SSs).
|
16106193 |
2005 |
|
Sarcoma
|
0.200 |
Biomarker
|
group |
BEFREE |
Furthermore, PDGFRA (located on 4q12) amplification was identified in five sarcomas.
|
11921282 |
2002 |
|
Sarcoma
|
0.200 |
Biomarker
|
group |
HPO |
|
|
|